Remove Clinical Development Remove Drug Development Remove Engineering
article thumbnail

Macrophage cell therapy: a new hope for chronic liver disease patients

Drug Target Review

Delivered as an autologous cell therapy, these macrophages have been engineered to increase their anti-inflammatory and anti-fibrotic properties, with the aim of delivering more potent and durable clinical effect to patients with end-stage liver disease.

Therapies 116
article thumbnail

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues. Asia, and Europe.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval

Advarra

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

article thumbnail

T-cell receptors offer window to the cell for a new class of cancer therapeutics

Drug Target Review

Using modern methods of cell sorting, next‑generation sequencing, artificial intelligence and synthetic biology, it is now feasible to isolate, analyse and engineer TCR sequences for commercial therapeutic purposes with much greater efficiency. Engineering soluble T-cell receptors for therapy. The FEBS Journal 288:6159–6173 (2021).

article thumbnail

BioDAOs are Community-Owned Research Translation Engines, Not Investment DAOs

Molecule Blog

Clinical development kicks off when the company files an IND with the FDA , progressing through Phase I for safety, Phase II for early signs of efficacy, and Phase III for determining full approval. How do BioDAOs differ from investment DAOs? To learn more about BioDAOs, check out bio.xyz and the BioDAO Bible.

article thumbnail

OTAT Town Hall on Cell Therapy CMC – The Recording is Available but Here’s an Appetizer

FDA Law Blog: Drug Discovery

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

article thumbnail

BioSpace Movers & Shakers, Jan. 1

The Pharma Data

where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. Prior to Taiho, he held the positions of senior vice president of Clinical Oncology and CMO at Geron Corporation. and CMO for Taiho Oncology, Inc.